EASL Clinical Practice Guidelines

References

[1]Shaneyfelt, T.M., Mayo-Smith, M.F., and Rothwangl, J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999; 281: 1900–1905
CrossRef | PubMed | Scopus (566)

[2]Krawitt, E.L. Autoimmune hepatitis. N Engl J Med. 2006; 354: 54–66
CrossRef | PubMed | Scopus (426)

[3]Lohse, A.W. and Mieli-Vergani, G. Autoimmune hepatitis. J Hepatol. 2011; 55: 171–182
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[4]Zachou, K., Muratori, P., Koukoulis, G.K., Granito, A., Gatselis, N., Fabbri, A. et al. Review article: autoimmune hepatitis – Current management and challenges. Aliment Pharmacol Ther. 2013; 38: 887–913
CrossRef | PubMed | Scopus (15)

[5]Manns, M.P., Lohse, A.W., and Vergani, D. Autoimmune hepatitis – Update 2015. J Hepatol. 2015; 62: S1–S186
PubMed

[6]Boberg, K.M., Aadland, E., Jahnsen, J., Raknerud, N., Stiris, M., and Bell, H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998; 33: 99–9103
CrossRef | PubMed | Scopus (295)

[7]Feld, J.J. and Heathcote, E.J. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol. 2003; 18: 1118–1128
CrossRef | PubMed | Scopus (57)

[8]Werner, M., Prytz, H., Ohlsson, B., Almer, S., Bjornsson, E., Bergquist, A. et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008; 43: 1232–1240
CrossRef | PubMed | Scopus (57)

[9]Ngu, J.H., Bechly, K., Chapman, B.A., Burt, M.J., Barclay, M.L., Gearry, R.B. et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J Gastroenterol Hepatol. 2010; 25: 1681–1686
CrossRef | PubMed | Scopus (40)

[10]Delgado, J.-S., Vodonos, A., Malnick, S., Kriger, O., Wilkof-Segev, R., Delgado, B. et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis. 2013; 14: 611–618
PubMed

[11]van Gerven, N.M.F., Verwer, B.J., Witte, B.I., van Erpecum, K.J., van Buuren, H.R., Maijers, I. et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014; 49: 1245–1254
CrossRef | PubMed | Scopus (1)

[12]Hurlburt, K.J., McMahon, B.J., Deubner, H., Hsu-Trawinski, B., Williams, J.L., and Kowdley, K.V. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002; 97: 2402–2407
CrossRef | PubMed

[13]Grønbæk, L., Vilstrup, H., and Jepsen, P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014; 60: 612–617
Abstract | Full Text | Full Text PDF | PubMed | Scopus (15)

[14]Minuk, G.Y., Liu, S., Kaita, K., Wong, S., Renner, E., Rempel, J. et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol. 2008; 22: 829–834
PubMed

[15]Verma, S., Torbenson, M., and Thuluvath, P.J. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007; 46: 1828–1835
CrossRef | PubMed | Scopus (50)

[16]Lim, K.N., Casanova, R.L., Boyer, T.D., and Bruno, C.J. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001; 96: 3390–3394
CrossRef | PubMed

[17]Munoz-Espinosa, L., Alarcon, G., Mercado-Moreira, A., Cordero, P., Caballero, E., Avalos, V. et al. Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients. Autoimmunity. 2011; 44: 543–548
CrossRef | PubMed | Scopus (3)

[18]Wong, R.J., Gish, R., Frederick, T., Bzowej, N., and Frenette, C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol. 2012; 46: 155–161
CrossRef | PubMed | Scopus (8)

[19]Levy, C., Naik, J., Giordano, C., Mandalia, A., O’Brien, C., Bhamidimarri, K.R. et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol. 2014; 12: 1398–1405
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[20]Zolfino, T., Heneghan, M.A., Norris, S., Harrison, P.M., Portmann, B.C., and McFarlane, I.G. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002; 50: 713–717
CrossRef | PubMed | Scopus (54)

[21]Czaja, A.J. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol. 2013; 7: 365–385
CrossRef | PubMed | Scopus (7)

[22]Leber, Waldenström J. Blutproteine und Nahrungseiweiss. Deutsch Z Verdau Stoffwechselkr. 1950; 15: 113–119

[23]Kunkel, H.G., Ahrens, E.H. Jr., Eigenmenger, W.J., Bougiovanni, A.M., and Slater, R.J. Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology. J Clin Invest. 1951; 30: 654 ([abstract])

[24]Cowling, D.C., Mackay, I.R., and Taft, L.I. Lupoid hepatitis. Lancet. 1956; 271: 1323–1326
PubMed

[25]Mackay, I.R., Weiden, S., and Hasker, J. Autoimmune hepatitis. Ann N Y Acad Sci. 1965; 124: 767–780
CrossRef | PubMed

[26]Johnson, P.J. and McFarlane, I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993; 18: 998–1005
CrossRef | PubMed

[27]Alvarez, F., Berg, P.A., Bianchi, F.B., Bianchi, L., Burroughs, A.K., Cancado, E.L. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31: 929–938
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1640)

[28]Hennes, E.M., Zeniya, M., Czaja, A.J., Pares, A., Dalekos, G.N., Krawitt, E.L. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48: 169–176
CrossRef | PubMed | Scopus (509)

[29]Muratori, P., Granito, A., Quarneti, C., Ferri, S., Menichella, R., Cassani, F. et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol. 2009; 50: 1210–1218
Abstract | Full Text | Full Text PDF | PubMed | Scopus (36)

[30]Schramm, C., Kanzler, S., zum Buschenfelde, K.H., Galle, P.R., and Lohse, A.W. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001; 96: 1587–1591
CrossRef | PubMed

[31]Peng, M., Li, Y., Zhang, M., Jiang, Y., Xu, Y., Tian, Y. et al. Clinical features in different age groups of patients with autoimmune hepatitis. Exp Ther Med. 2014; 7: 145–148
PubMed

[32]Chen, J., Eslick, G.D., and Weltman, M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther. 2014; 39: 117–124
CrossRef | PubMed | Scopus (2)

[33]Abe, M., Mashiba, T., Zeniya, M., Yamamoto, K., Onji, M., Tsubouchi, H. et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011; 46: 1136–1141
CrossRef | PubMed | Scopus (36)

[34]Manns, M.P., Czaja, A.J., Gorham, J.D., Krawitt, E.L., Mieli-Vergani, G., Vergani, D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51: 2193–2213
CrossRef | PubMed | Scopus (387)

[35]Al-Chalabi, T., Boccato, S., Portmann, B.C., McFarlane, I.G., and Heneghan, M.A. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006; 45: 575–583
Abstract | Full Text | Full Text PDF | PubMed | Scopus (94)

[36]Schramm, C., Wahl, I., Weiler-Normann, C., Voigt, K., Wiegard, C., Glaubke, C. et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol. 2014; 60: 618–624
Abstract | Full Text | Full Text PDF | PubMed | Scopus (2)

[37]Stravitz, R.T., Lefkowitch, J.H., Fontana, R.J., Gershwin, M.E., Leung, P.S., Sterling, R.K. et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011; 53: 517–526
CrossRef | PubMed | Scopus (64)

[38]Takahashi, H. and Zeniya, M. Acute presentation of autoimmune hepatitis: Does it exist? A published work review. Hepatol Res. 2011; 41: 498–504
CrossRef | PubMed | Scopus (15)

[39]Ferrari, R., Pappas, G., Agostinelli, D., Muratori, P., Muratori, L., Lenzi, M. et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the ‘acute’ type. QJM. 2004; 97: 407–412
CrossRef | PubMed | Scopus (40)

[40]Gleeson, D. and Heneghan, M.A. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011; 60: 1611–1629
CrossRef | PubMed | Scopus (54)

[41]Czaja, A.J. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011; 25: 689–700
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[42]Miyake, Y., Iwasaki, Y., Terada, R., Onishi, T., Okamoto, R., Sakai, N. et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006; 23: 1347–1353
CrossRef | PubMed | Scopus (38)

[43]Karkhanis, J., Verna, E.C., Chang, M.S., Stravitz, R.T., Schilsky, M., Lee, W.M. et al. Steroid use in acute liver failure. Hepatology. 2014; 59: 612–621
CrossRef | PubMed | Scopus (13)

[44]Feld, J.J., Dinh, H., Arenovich, T., Marcus, V.A., Wanless, I.R., and Heathcote, E.J. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005; 42: 53–62
CrossRef | PubMed | Scopus (132)

[45]Zachou, K., Gatselis, N., Papadamou, G., Rigopoulou, E.I., and Dalekos, G.N. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol. 2011; 55: 636–646
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[46]Landeira, G., Morise, S., Fassio, E., Ramonet, M., Alvarez, E., Caglio, P. et al. Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis. Ann Hepatol. 2012; 11: 100–106
PubMed

[47]Ngu, J.H., Gearry, R.B., Frampton, C.M., and Stedman, C.A. Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study. Hepatology. 2013; 57: 2399–2406
CrossRef | PubMed | Scopus (12)

[48]Manns, M., Gerken, G., Kyriatsoulis, A., Staritz, M., and Meyer zum Büschenfelde, K.H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987; 1: 292–294
Abstract | PubMed | Scopus (281)

[49]Kanzler, S., Weidemann, C., Gerken, G., Lohr, H.F., Galle, P.R., Meyer zum Büschenfelde, K.H. et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999; 31: 635–640
Abstract | Full Text | Full Text PDF | PubMed | Scopus (95)

[50]Czaja, A.J., Donaldson, P.T., and Lohse, A.W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002; 97: 413–419
CrossRef | PubMed

[51]Boberg, K.M., Chapman, R.W., Hirschfield, G.M., Lohse, A.W., Manns, M.P., Schrumpf, E. et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011; 54: 374–385
Abstract | Full Text | Full Text PDF | PubMed | Scopus (134)

[52]Gregorio, G.V., Portmann, B., Karani, J., Harrison, P., Donaldson, P.T., Vergani, D. et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001; 33: 544–553
CrossRef | PubMed | Scopus (313)

[53]Rojas, C.P., Bodicharla, R., Campuzano-Zuluaga, G., Hernandez, L., and Rodriguez, M.M. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol. 2014; 33: 202–209
CrossRef | PubMed | Scopus (1)

[54]Mieli-Vergani, G., Heller, S., Jara, P., Vergani, D., Chang, M.H., Fujisawa, T. et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2009; 49: 158–164
CrossRef | PubMed | Scopus (71)

[55]Gatselis, N.K., Zachou, K., Papamichalis, P., Koukoulis, G.K., Gabeta, S., Dalekos, G.N. et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. Dig Liver Dis. 2010; 42: 807–812
Abstract | Full Text | Full Text PDF | PubMed | Scopus (20)

[56]Lohse, A.W., zum Buschenfelde, K.H., Franz, B., Kanzler, S., Gerken, G., and Dienes, H.P. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999; 29: 1078–1084
CrossRef | PubMed

[57]Chazouilleres, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., and Poupon, R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998; 28: 296–301
CrossRef | PubMed | Scopus (370)

[58]Heurgue, A., Vitry, F., Diebold, M.D., Yaziji, N., Bernard-Chabert, B., Pennaforte, J.L. et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007; 31: 17–25
CrossRef | PubMed

[59]Kuiper, E.M., Zondervan, P.E., and van Buuren, H.R. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010; 8: 530–534
Abstract | Full Text | Full Text PDF | PubMed | Scopus (34)

[60]European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51: 237–267
Abstract | Full Text | Full Text PDF | PubMed | Scopus (469)

[61]Gohlke, F., Lohse, A.W., Dienes, H.P., Lohr, H., Marker-Hermann, E., Gerken, G. et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol. 1996; 24: 699–705
Abstract | Full Text PDF | PubMed | Scopus (127)

[62]Lewin, M., Vilgrain, V., Ozenne, V., Lemoine, M., Wendum, D., Paradis, V. et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology. 2009; 50: 528–537
CrossRef | PubMed | Scopus (27)

[63]Czaja, A.J. and Carpenter, H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001; 34: 659–665
CrossRef | PubMed | Scopus (112)

[64]Luth, S., Kanzler, S., Frenzel, C., Kasper, H.U., Dienes, H.P., Schramm, C. et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009; 43: 75–80
CrossRef | PubMed | Scopus (27)

[65]Zenouzi, R. and Lohse, A.W. Long-term outcome in PSC/AIH “overlap syndrome”: does immunosuppression also treat the PSC component?. J Hepatol. 2014; 61: 1189–1191
Abstract | Full Text | Full Text PDF | PubMed

[66]Chung, H., Watanabe, T., Kudo, M., Maenishi, O., Wakatsuki, Y., and Chiba, T. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int. 2010; 30: 222–231
CrossRef | PubMed | Scopus (32)

[67]Umemura, T., Zen, Y., Hamano, H., Joshita, S., Ichijo, T., Yoshizawa, K. et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol. 2011; 46: 48–55
CrossRef | PubMed | Scopus (34)

[68]Trivedi, P.J. and Hirschfield, G.M. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther. 2012; 36: 517–533
CrossRef | PubMed | Scopus (28)

[69]Castiella, A., Zapata, E., Lucena, M.I., and Andrade, R.J. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol. 2014; 6: 160–168
CrossRef | PubMed | Scopus (3)

[70]Weiler-Normann, C. and Schramm, C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011; 55: 747–749
Abstract | Full Text | Full Text PDF | PubMed | Scopus (21)

[71]Beaune, P., Dansette, P.M., Mansuy, D., Kiffel, L., Finck, M., Amar, C. et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A. 1987; 84: 551–555
CrossRef | PubMed | Scopus (207)

[72]Bourdi, M., Larrey, D., Nataf, J., Bernuau, J., Pessayre, D., Iwasaki, M. et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest. 1990; 85: 1967–1973
CrossRef | PubMed

[73]Appleyard, S., Saraswati, R., and Gorard, D.A. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep. 2010; 4: 311
CrossRef | PubMed | Scopus (15)

[74]Bjornsson, E., Talwalkar, J., Treeprasertsuk, S., Kamath, P.S., Takahashi, N., Sanderson, S. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010; 51: 2040–2048
CrossRef | PubMed | Scopus (104)

[75]Suzuki, A., Brunt, E.M., Kleiner, D.E., Miquel, R., Smyrk, T.C., Andrade, R.J. et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011; 54: 931–939
CrossRef | PubMed | Scopus (62)

[76]Fontana, R.J., Seeff, L.B., Andrade, R.J., Bjornsson, E., Day, C.P., Serrano, J. et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010; 52: 730–742
CrossRef | PubMed | Scopus (102)

[77]Heurgué, A., Bernard-Chabert, B., Diebold, M., Vitry, F., Louvet, H., and Geoffroy, P. Drug-induced autoimmune hepatitis: a frequent disorder. Gut. 2007; 56: A271
CrossRef | PubMed | Scopus (14)

[78]Chalasani, N., Fontana, R.J., Bonkovsky, H.L., Watkins, P.B., Davern, T., Serrano, J. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135: 1924–1934 (1934, e1921–e1924)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (279)

[79]Buchel, E., Van Steenbergen, W., Nevens, F., and Fevery, J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol. 2002; 97: 3160–3165
CrossRef | PubMed

[80]Samuel, D., Riordan, S., Strasser, S., Kurtovic, J., Singh-Grewel, I., and Koorey, D. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol. 2004; 2: 622–624
Abstract | Full Text | Full Text PDF | PubMed | Scopus (22)

[81]Westbrook, R.H., Yeoman, A.D., Kriese, S., and Heneghan, M.A. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 2012; 38: J239–J244
CrossRef | PubMed | Scopus (22)

[82]Heneghan, M.A., Norris, S.M., O’Grady, J.G., Harrison, P.M., and McFarlane, I.G. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001; 48: 97–102
CrossRef | PubMed | Scopus (137)

[83]Muratori, P., Loffreda, S., Muratori, L., Ferrari, R., Afandi, K., Cassani, F. et al. Spontaneous remission of autoimmune hepatitis during pregnancy. Dig Liver Dis. 2002; 34: 608–609
Abstract | Full Text PDF | PubMed | Scopus (6)

[84]Terrabuio, D.R., Abrantes-Lemos, C.P., Carrilho, F.J., and Cancado, E.L. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol. 2009; 43: 350–356
CrossRef | PubMed | Scopus (27)

[85]Vento, S. and Cainelli, F. Is there a role for viruses in triggering autoimmune hepatitis?. Autoimmun Rev. 2004; 3: 61–69
CrossRef | PubMed | Scopus (30)

[86]Zellos, A., Spoulou, V., Roma-Giannikou, E., Karentzou, O., Dalekos, G.N., and Theodoridou, M. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. Ann Hepatol. 2013; 12: 147–151
PubMed

[87]Dalekos, G.N., Wedemeyer, H., Obermayer-Straub, P., Kayser, A., Barut, A., Frank, H. et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol. 1999; 30: 366–375
Abstract | Full Text | Full Text PDF | PubMed | Scopus (77)

[88]Muratori, L., Lenzi, M., Cataleta, M., Giostra, F., Cassani, F., Ballardini, G. et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol. 1994; 21: 199–203
Abstract | Full Text PDF | PubMed

[89]Vento, S., Cainelli, F., Renzini, C., and Concia, E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet. 1997; 350: 1298–1299
Abstract | Full Text | Full Text PDF | PubMed

[90]Mieli-Vergani, G. and Vergani, D. De novo autoimmune hepatitis after liver transplantation. J Hepatol. 2004; 40: 3–7
Abstract | Full Text | Full Text PDF | PubMed | Scopus (88)

[91]Montano-Loza, A.J., Vargas-Vorackova, F., Ma, M., Bain, V.G., Burak, K., Kumar, T. et al. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. Liver Int. 2012; 32: 1426–1433
CrossRef | PubMed | Scopus (2)

[92]Fiel, M.I. and Schiano, T.D. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant. 2012; 17: 287–292
CrossRef | PubMed

[93]Rigopoulou, E.I., Dalekos, G., and Bogdanos, D.P. How common are connective tissue disorders in patients with autoimmune hepatitis?. Semin Arthritis Rheum. 2007; 36: 332 ([author reply 333])
Abstract | Full Text | Full Text PDF | PubMed

[94]Panetta, F., Nobili, V., Sartorelli, M.R., Papa, R.E., Ferretti, F., Alterio, A. et al. Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management. Paediatr Drugs. 2012; 14: 35–41
CrossRef | PubMed | Scopus (9)

[95]Teufel, A., Weinmann, A., Kahaly, G.J., Centner, C., Piendl, A., Worns, M. et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010; 44: 208–213
CrossRef | PubMed | Scopus (51)

[96]Obermayer-Straub, P., Perheentupa, J., Braun, S., Kayser, A., Barut, A., Loges, S. et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology. 2001; 121: 668–677
Abstract | Full Text | Full Text PDF | PubMed

[97]Teufel, A., Weinmann, A., Centner, C., Piendl, A., Lohse, A.W., Galle, P.R. et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009; 15: 578–582
CrossRef | PubMed | Scopus (34)

[98]Yeoman, A.D., Al-Chalabi, T., Karani, J.B., Quaglia, A., Devlin, J., Mieli-Vergani, G. et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008; 48: 863–870
CrossRef | PubMed | Scopus (72)

[99]Ngu, J.H., Gearry, R.B., Frampton, C.M., and Stedman, C.A. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology. 2012; 55: 522–529
CrossRef | PubMed | Scopus (32)

[100]Migita, K., Watanabe, Y., Jiuchi, Y., Nakamura, Y., Saito, A., Yagura, M. et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012; 32: 837–844
CrossRef | PubMed | Scopus (14)

[101]Montano-Loza, A.J., Carpenter, H.A., and Czaja, A.J. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008; 103: 1944–1951
CrossRef | PubMed | Scopus (39)

[102]Hino-Arinaga, T., Ide, T., Kuromatsu, R., Miyajima, I., Ogata, K., Kuwahara, R. et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2012; 47: 569–576
CrossRef | PubMed | Scopus (12)

[103]Czaja, A.J. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013; 58: 1459–1476
CrossRef | PubMed | Scopus (0)

[104]Al-Chalabi, T., Underhill, J.A., Portmann, B.C., McFarlane, I.G., and Heneghan, M.A. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008; 48: 140–147
Abstract | Full Text | Full Text PDF | PubMed | Scopus (57)

[105]Floreani, A., Niro, G., Rosa Rizzotto, E., Antoniazzi, S., Ferrara, F., Carderi, I. et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006; 24: 1051–1057
CrossRef | PubMed | Scopus (49)

[106]Fujiwara, K., Fukuda, Y., and Yokosuka, O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008; 43: 951–958
CrossRef | PubMed | Scopus (36)

[107]Yasui, S., Fujiwara, K., Yonemitsu, Y., Oda, S., Nakano, M., and Yokosuka, O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011; 46: 378–390
CrossRef | PubMed | Scopus (28)

[108]Luth, S., Herkel, J., Kanzler, S., Frenzel, C., Galle, P.R., Dienes, H.P. et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008; 42: 926–930
CrossRef | PubMed | Scopus (47)

[109]Georgiadou, S.P., Zachou, K., Liaskos, C., Gabeta, S., Rigopoulou, E.I., and Dalekos, G.N. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int. 2009; 29: 434–442
CrossRef | PubMed | Scopus (21)

[110]Azhar, A., Niazi, M.A., Tufail, K., Malek, A.H., Balasubramanian, M., and Araya, V. A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome. Gastroenterol Hepatol (N Y). 2010; 6: 233–236
PubMed

[111]Rigopoulou, E.I., Zachou, K., Gatselis, N., Koukoulis, G.K., and Dalekos, G.N. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol. 2013; 13: 127–135
PubMed

[112]Vergani, D., Alvarez, F., Bianchi, F.B., Cancado, E.L., Mackay, I.R., Manns, M.P. et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004; 41: 677–683
Abstract | Full Text | Full Text PDF | PubMed | Scopus (176)

[113]Bogdanos, D.P., Invernizzi, P., Mackay, I.R., and Vergani, D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008; 14: 3374–3387
CrossRef | PubMed | Scopus (108)

[114]Czaja, A.J. and Homburger, H.A. Autoantibodies in liver disease. Gastroenterology. 2001; 120: 239–249
Abstract | Full Text | Full Text PDF | PubMed

[115]Frenzel, C., Herkel, J., Luth, S., Galle, P.R., Schramm, C., and Lohse, A.W. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol. 2006; 101: 2731–2736
CrossRef | PubMed | Scopus (31)

[116]Villalta, D., Bizzaro, N., Da Re, M., Tozzoli, R., Komorowski, L., and Tonutti, E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity. 2008; 41: 105–110
CrossRef | PubMed | Scopus (16)

[117]Granito, A., Muratori, L., Muratori, P., Pappas, G., Guidi, M., Cassani, F. et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol. 2006; 59: 280–284
CrossRef | PubMed | Scopus (47)

[118]Liaskos, C., Bogdanos, D.P., Davies, E.T., and Dalekos, G.N. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol. 2007; 60: 107–108
CrossRef | PubMed | Scopus (12)

[119]Cassani, F., Cataleta, M., Valentini, P., Muratori, P., Giostra, F., Francesconi, R. et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997; 26: 561–566
CrossRef | PubMed

[120]Bortolotti, F., Vajro, P., Balli, F., Giacchino, R., Crivellaro, C., Barbera, C. et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol. 1996; 25: 614–620
Abstract | Full Text PDF | PubMed | Scopus (78)

[121]Lenzi, M., Manotti, P., Muratori, L., Cataleta, M., Ballardini, G., Cassani, F. et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut. 1995; 36: 749–754
CrossRef | PubMed

[122]Dalekos, G.N., Makri, E., Loges, S., Obermayer-Straub, P., Zachou, K., Tsikrikas, T. et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol. 2002; 14: 35–42
CrossRef | PubMed | Scopus (27)

[123]Ferri, S., Muratori, L., Quarneti, C., Muratori, P., Menichella, R., Pappas, G. et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol. 2009; 50: 1093–1101
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[124]Kerkar, N., Choudhuri, K., Ma, Y., Mahmoud, A., Bogdanos, D.P., Muratori, L. et al. Cytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol. 2003; 170: 1481–1489
CrossRef | PubMed

[125]Lohse, A.W., Obermayer-Straub, P., Gerken, G., Brunner, S., Altes, U., Dienes, H.P. et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease – Possible association with a steroid-resistant transplant rejection episode. J Hepatol. 1999; 31: 149–155
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[126]Wies, I., Brunner, S., Henninger, J., Herkel, J., Kanzler, S., Meyer zum Buschenfelde, K.H. et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000; 355: 1510–1515
Abstract | Full Text | Full Text PDF | PubMed

[127]Palioura, S., Sherrer, R.L., Steitz, T.A., Soll, D., and Simonovic, M. The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation. Science. 2009; 325: 321–325
CrossRef | PubMed | Scopus (55)

[128]Baeres, M., Herkel, J., Czaja, A.J., Wies, I., Kanzler, S., Cancado, E.L. et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002; 51: 259–264
CrossRef | PubMed | Scopus (92)

[129]Zachou, K., Gampeta, S., Gatselis, N.K., Oikonomou, K., Goulis, J., Manoussakis, M.N. et al. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int. 2015; 35: 660–672
CrossRef | PubMed | Scopus (1)

[130]Liaskos, C., Bogdanos, P.P., Rigopoulou, E.I., Norman, G.L., Shurns, Z., Al-Chalabi, T. et al. Antibody responses specific for soluble liver antigen co-occur with RO-52 autoantibodies in patients with autoimmune hepatitis. J Hepatol. 2007; 46: S250
Abstract | Full Text PDF

[131]Eyraud, V., Chazouilleres, O., Ballot, E., Corpechot, C., Poupon, R., and Johanet, C. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int. 2009; 29: 857–864
CrossRef | PubMed | Scopus (21)

[132]Montano-Loza, A.J., Shums, Z., Norman, G.L., and Czaja, A.J. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012; 32: 85–92
CrossRef | PubMed | Scopus (25)

[133]Ma, Y., Okamoto, M., Thomas, M.G., Bogdanos, D.P., Lopes, A.R., Portmann, B. et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002; 35: 658–664
CrossRef | PubMed | Scopus (157)

[134]Czaja, A.J., Shums, Z., and Norman, G.L. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity. 2004; 37: 195–201
CrossRef | PubMed | Scopus (39)

[135]Targan, S.R., Landers, C., Vidrich, A., and Czaja, A.J. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995; 108: 1159–1166
Abstract | Full Text PDF | PubMed | Scopus (142)

[136]Zauli, D., Ghetti, S., Grassi, A., Descovich, C., Cassani, F., Ballardini, G. et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997; 25: 1105–1107
CrossRef | PubMed

[137]Terjung, B., Spengler, U., Sauerbruch, T., and Worman, H.J. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000; 119: 310–322
Abstract | Full Text | Full Text PDF | PubMed

[138]Terjung, B., Worman, H.J., Herzog, V., Sauerbruch, T., and Spengler, U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001; 126: 37–46
CrossRef | PubMed | Scopus (43)

[139]O’Brien, C., Joshi, S., Feld, J.J., Guindi, M., Dienes, H.P., and Heathcote, E.J. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008; 48: 550–556
CrossRef | PubMed | Scopus (64)

[140]Farias, A.Q., Goncalves, L.L., Bittencourt, P.L., De Melo, E.S., Abrantes-Lemos, C.P., Porta, G. et al. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. J Gastroenterol Hepatol. 2006; 21: 887–893
CrossRef | PubMed | Scopus (22)

[141]Kerkar, N., Ma, Y., Davies, E.T., Cheeseman, P., Mieli-Vergani, G., and Vergani, D. Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays. J Clin Pathol. 2002; 55: 906–909
CrossRef | PubMed | Scopus (4)

[142]Gassert, D.J., Garcia, H., Tanaka, K., and Reinus, J.F. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007; 52: 2433–2437
CrossRef | PubMed | Scopus (33)

[143]Potthoff, A., Deterding, K., Trautwein, C., Flemming, P., Strassburg, C.P., Manns, M.P. et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007; 45: 15–19
CrossRef | PubMed | Scopus (17)

[144]Czaja, A.J. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999; 30: 394–401
Abstract | Full Text | Full Text PDF | PubMed | Scopus (123)

[145]Gregorio, G.V., McFarlane, B., Bracken, P., Vergani, D., and Mieli-Vergani, G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity. 2002; 35: 515–519
CrossRef | PubMed | Scopus (37)

[146]Muratori, L., Cataleta, M., Muratori, P., Lenzi, M., and Bianchi, F.B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998; 42: 721–726
CrossRef | PubMed

[147]Denzer, U., Arnoldy, A., Kanzler, S., Galle, P.R., Dienes, H.P., and Lohse, A.W. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol. 2007; 41: 103–110
CrossRef | PubMed | Scopus (33)

[148]Denzer, U., Helmreich-Becker, I., Galle, P.R., and Lohse, A.W. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol. 2003; 98: 893–900
CrossRef | PubMed | Scopus (38)

[149]Helmreich-Becker, I., Meyer zum Buschenfelde, K.H., and Lohse, A.W. Safety and feasibility of a new minimally invasive diagnostic laparoscopy technique. Endoscopy. 1998; 30: 756–762
CrossRef | PubMed

[150]Czaja, A.J. and Carpenter, H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993; 105: 1824–1832
PubMed

[151]Czaja, A.J. and Carpenter, H.A. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007; 5: 898–907
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[152]Desmet, V.J., Gerber, M., Hoofnagle, J.H., Manns, M., and Scheuer, P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 1513–1520
CrossRef | PubMed

[153]Dienes, H.P., Erberich, H., Dries, V., Schirmacher, P., and Lohse, A. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis. 2002; 6: 349–362 (vi)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[154]Kessler, W.R., Cummings, O.W., Eckert, G., Chalasani, N., Lumeng, L., and Kwo, P.Y. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004; 2: 625–631
Abstract | Full Text | Full Text PDF | PubMed | Scopus (109)

[155]Burgart, L.J., Batts, K.P., Ludwig, J., Nikias, G.A., and Czaja, A.J. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995; 19: 699–708
CrossRef | PubMed

[156]Hofer, H., Oesterreicher, C., Wrba, F., Ferenci, P., and Penner, E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006; 59: 246–249
CrossRef | PubMed | Scopus (46)

[157]Zen, Y., Notsumata, K., Tanaka, N., and Nakanuma, Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis?. Hum Pathol. 2007; 38: 1669–1675
Abstract | Full Text | Full Text PDF | PubMed | Scopus (26)

[158]Okano, N., Yamamoto, K., Sakaguchi, K., Miyake, Y., Shimada, N., Hakoda, T. et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003; 25: 263–270
CrossRef | PubMed | Scopus (56)

[159]Czaja, A.J., Muratori, P., Muratori, L., Carpenter, H.A., and Bianchi, F.B. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 2004; 24: 322–329
CrossRef | PubMed

[160]Schalm, S.W., Korman, M.G., Summerskill, W.H., Czaja, A.J., and Baggenstoss, A.H. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977; 22: 973–980
CrossRef | PubMed | Scopus (48)

[161]Helmreich-Becker, I. and Lohse, A.W. Minilaparoskopie in der Leberdiagnostik – ein Vorteil?. Z Gastroenterol. 2001; 39: 7–9
PubMed

[162]Anastasiou, J., Alisa, A., Virtue, S., Portmann, B., Murray-Lyon, I., and Williams, R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur J Gastroenterol Hepatol. 2010; 22: 474–480
CrossRef | PubMed | Scopus (15)

[163]Gutkowski, K., Hartleb, M., Kacperek-Hartleb, T., Kajor, M., Mazur, W., Zych, W. et al. Laboratory-based scoring system for prediction of hepatic inflammatory activity in patients with autoimmune hepatitis. Liver Int. 2013; 33: 1370–1377
CrossRef | PubMed

[164]Kaya, M., Angulo, P., and Lindor, K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000; 33: 537–542
Abstract | Full Text | Full Text PDF | PubMed

[165]Talwalkar, J.A., Keach, J.C., Angulo, P., and Lindor, K.D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002; 97: 1191–1197
CrossRef | PubMed

[166]Czaja, A.J. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008; 48: 1540–1548
CrossRef | PubMed | Scopus (94)

[167]Czaja, A. and Carpenter, H.A. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996; 41: 305–314
CrossRef | PubMed | Scopus (100)

[168]Qiu, D., Wang, Q., Wang, H., Xie, Q., Zang, G., Jiang, H. et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol. 2011; 54: 340–347
Abstract | Full Text | Full Text PDF | PubMed | Scopus (35)

[169]Yeoman, A.D., Westbrook, R.H., Al-Chalabi, T., Carey, I., Heaton, N.D., Portmann, B.C. et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009; 50: 538–545
CrossRef | PubMed | Scopus (57)

[170]Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J. et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol. 2010; 105: 345–353
CrossRef | PubMed | Scopus (46)

[171]Muratori, P., Granito, A., Pappas, G., Pendino, G.M., Quarneti, C., Cicola, R. et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009; 104: 1420–1425
CrossRef | PubMed | Scopus (47)

[172]Lohse, A.W. Recognizing autoimmune hepatitis: scores help, but no more. J Hepatol. 2011; 54: 193–194
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[173]Yamamoto, K., Miyake, Y., Ohira, H., Suzuki, Y., Zeniya, M., Onji, M. et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res. 2013; 43: 630–638
CrossRef | PubMed | Scopus (9)

[174]Fujiwara, K., Yasui, S., Tawada, A., Fukuda, Y., Nakano, M., and Yokosuka, O. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int. 2011; 31: 1013–1020
CrossRef | PubMed | Scopus (18)

[175]Cook, G.C., Mulligan, R., and Sherlock, S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971; 40: 159–185
CrossRef | PubMed

[176]Soloway, R.D., Summerskill, W.H., Baggenstoss, A.H., Geall, M.G., Gitnick, G.L., Elveback, I.R. et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972; 63: 820–833
PubMed

[177]Murray-Lyon, I.M., Stern, R.B., and Williams, R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973; 1: 735–737
Abstract | PubMed

[178]Kirk, A.P., Jain, S., Pocock, S., Thomas, H.C., and Sherlock, S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980; 21: 78–83
CrossRef | PubMed

[179]Lamers, M.M., van Oijen, M.G., Pronk, M., and Drenth, J.P. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010; 53: 191–198
Abstract | Full Text | Full Text PDF | PubMed | Scopus (37)

[180]De Groote, J., Fevery, J., and Lepoutre, L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut. 1978; 19: 510–513
CrossRef | PubMed

[181]Czaja, A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009; 29: 816–823
CrossRef | PubMed | Scopus (35)

[182]Dufour, J.F., Zimmermann, M., and Reichen, J. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol. 2002; 37: 748–752
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[183]Kogan, J., Safadi, R., Ashur, Y., Shouval, D., and Ilan, Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002; 35: 75–81
CrossRef | PubMed | Scopus (63)

[184]Keating, J.J., O’Brien, C.J., Stellon, A.J., Portmann, B.C., Johnson, R.D., Johnson, P.J. et al. Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: an analysis of 204 patients. Q J Med. 1987; 62: 59–66
PubMed

[185]Tan, P., Marotta, P., Ghent, C., and Adams, P. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int. 2005; 25: 728–733
CrossRef | PubMed | Scopus (13)

[186]Summerskill, W.H., Korman, M.G., Ammon, H.V., and Baggenstoss, A.H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975; 16: 876–883
CrossRef | PubMed

[187]Tage-Jensen, U., Schlichting, P., Aldershvile, J., Andersen, P., Dietrichson, O., Hardt, F. et al. Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver. 1982; 2: 95–103
CrossRef | PubMed

[188]Schramm, C., Weiler-Normann, C., Wiegard, C., Hellweg, S., Muller, S., and Lohse, A.W. Treatment response in patients with autoimmune hepatitis. Hepatology. 2010; 52: 2247–2248
CrossRef | PubMed | Scopus (14)

[189]Werner, M., Wallerstedt, S., Lindgren, S., Almer, S., Bjornsson, E., Bergquist, A. et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010; 45: 457–467
CrossRef | PubMed | Scopus (23)

[190]Miyake, Y., Iwasaki, Y., Terada, R., Okamaoto, R., Ikeda, H., Makino, Y. et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006; 24: 1197–1205
CrossRef | PubMed | Scopus (28)

[191]Verma, S., Gunuwan, B., Mendler, M., Govindrajan, S., and Redeker, A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004; 99: 1510–1516
CrossRef | PubMed | Scopus (88)

[192]Muratori, L., Muratori, P., Lanzoni, G., Ferri, S., and Lenzi, M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 2010; 52: 1857
CrossRef | PubMed | Scopus (12)

[193]Manns, M.P., Woynarowski, M., Kreisel, W., Lurie, Y., Rust, C., Zuckerman, E. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010; 139: 1198–1206
Abstract | Full Text | Full Text PDF | PubMed | Scopus (117)

[194]Danielsson, A. and Prytz, H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994; 8: 585–590
CrossRef | PubMed

[195]Wiegand, J., Schuler, A., Kanzler, S., Lohse, A., Beuers, U., Kreisel, W. et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005; 25: 927–934
CrossRef | PubMed | Scopus (71)

[196]Csepregi, A., Rocken, C., Treiber, G., and Malfertheiner, P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006; 12: 1362–1366
PubMed

[197]Czaja, A.J. and Lindor, K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000; 119: 1312–1316
Abstract | Full Text | Full Text PDF | PubMed

[198]Geier, A., Gartung, C., Dietrich, C.G., Wasmuth, H.E., Reinartz, P., and Matern, S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003; 9: 2681–2685
CrossRef | PubMed

[199]Efe, C., Ozaslan, E., Kav, T., Purnak, T., Shorbagi, A., Ozkayar, O. et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. 2012; 11: 330–334
CrossRef | PubMed | Scopus (11)

[200]Czaja, A.J. Drug choices in autoimmune hepatitis: part A-Steroids. Expert Rev Gastroenterol Hepatol. 2012; 6: 603–615
CrossRef | PubMed | Scopus (13)

[201]Czaja, A.J., Menon, K.V., and Carpenter, H.A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002; 35: 890–897
CrossRef | PubMed | Scopus (99)

[202]Sanchez-Urdazpal, L., Czaja, A.J., van Hoek, B., Krom, R.A., and Wiesner, R.H. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992; 15: 215–221
CrossRef | PubMed

[203]Montano-Loza, A.J., Carpenter, H.A., and Czaja, A.J. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007; 46: 1138–1145
CrossRef | PubMed | Scopus (72)

[204]Yeoman, A.D., Westbrook, R.H., Zen, Y., Maninchedda, P., Portmann, B.C., Devlin, J. et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011; 53: 926–934
CrossRef | PubMed | Scopus (23)

[205]Czaja, A.J., Rakela, J., and Ludwig, J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988; 95: 448–453
PubMed

[206]Ichai, P., Duclos-Vallee, J.C., Guettier, C., Hamida, S.B., Antonini, T., Delvart, V. et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007; 13: 996–1003
CrossRef | PubMed | Scopus (102)

[207]Schalm, S.W., Ammon, H.V., and Summerskill, W.H. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976; 8: 221–227
PubMed

[208]Hoeroldt, B., McFarlane, E., Dube, A., Basumani, P., Karajeh, M., Campbell, M.J. et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011; 140: 1980–1989
Abstract | Full Text | Full Text PDF | PubMed | Scopus (42)

[209]Kanzler, S., Gerken, G., Lohr, H., Galle, P.R., Meyer zum Buschenfelde, K.H., and Lohse, A.W. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. 2001; 34: 354–355
Abstract | Full Text | Full Text PDF | PubMed | Scopus (79)

[210]Czaja, A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009; 51: 161–167
Abstract | Full Text | Full Text PDF | PubMed | Scopus (38)

[211]Montano-Loza, A.J., Carpenter, H.A., and Czaja, A.J. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007; 102: 1005–1012
CrossRef | PubMed | Scopus (81)

[212]Czaja, A.J., Wolf, A.M., and Baggenstoss, A.H. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981; 80: 687–692
PubMed

[213]Hartl, J., Ehlken, H., Weiler-Normann, C., Sebode, M., Kreuels, B., Pannicke, N. et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 2015; 62: 642–646
Abstract | Full Text | Full Text PDF | PubMed

[214]Hegarty, J.E., Nouri Aria, K.T., Portmann, B., Eddleston, A.L., and Williams, R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983; 3: 685–689
CrossRef | PubMed

[215]Czaja, A.J., Ludwig, J., Baggenstoss, A.H., and Wolf, A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med. 1981; 304: 5–9
CrossRef | PubMed

[216]Czaja, A.J., Beaver, S.J., and Shiels, M.T. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987; 92: 215–219
PubMed

[217]Heneghan, M.A. and McFarlane, I.G. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology. 2002; 35: 7–13
CrossRef | PubMed | Scopus (145)

[218]Czaja, A.J., Davis, G.L., Ludwig, J., and Taswell, H.F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984; 4: 622–627
CrossRef | PubMed

[219]Al-Chalabi, T. and Heneghan, M.A. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?. Am J Gastroenterol. 2007; 102: 1013–1015
CrossRef | PubMed | Scopus (16)

[220]Montano-Loza, A.J., Carpenter, H.A., and Czaja, A.J. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007; 27: 507–515
CrossRef | PubMed | Scopus (59)

[221]Stellon, A.J., Keating, J.J., Johnson, P.J., McFarlane, I.G., and Williams, R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988; 8: 781–784
CrossRef | PubMed

[222]Johnson, P.J., McFarlane, I.G., and Williams, R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995; 333: 958–963
CrossRef | PubMed | Scopus (265)

[223]Meyer zum Buschenfelde, K.H. and Lohse, A.W. Autoimmune hepatitis. N Engl J Med. 1995; 333: 1004–1005
CrossRef | PubMed | Scopus (33)

[224]Chan, G.L., Erdmann, G.R., Gruber, S.A., Matas, A.J., and Canafax, D.M. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990; 30: 358–363
CrossRef | PubMed

[225]Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43: 329–339
CrossRef | PubMed | Scopus (402)

[226]Dubinsky, M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004; 2: 731–743
Abstract | Full Text | Full Text PDF | PubMed | Scopus (128)

[227]Allison, A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000; 47: 63–83
CrossRef | PubMed | Scopus (224)

[228]Ben Ari, Z., Mehta, A., Lennard, L., and Burroughs, A.K. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol. 1995; 23: 351–354
PubMed

[229]Cuffari, C., Dassopoulos, T., Turnbough, L., Thompson, R.E., and Bayless, T.M. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004; 2: 410–417
Abstract | Full Text | Full Text PDF | PubMed | Scopus (104)

[230]Langley, P.G., Underhill, J., Tredger, J.M., Norris, S., and McFarlane, I.G. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol. 2002; 37: 441–447
Abstract | Full Text | Full Text PDF | PubMed | Scopus (62)

[231]Heneghan, M.A., Allan, M.L., Bornstein, J.D., Muir, A.J., and Tendler, D.A. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol. 2006; 45: 584–591
Abstract | Full Text | Full Text PDF | PubMed | Scopus (49)

[232]Czaja, A.J. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther. 2013; 38: 343–364
CrossRef | PubMed | Scopus (15)

[233]Czaja, A.J. and Carpenter, H.A. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci. 2006; 51: 968–975
CrossRef | PubMed | Scopus (34)

[234]Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J.O. et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997; 62: 60–73
CrossRef | PubMed | Scopus (306)

[235]Kaskas, B.A., Louis, E., Hindorf, U., Schaeffeler, E., Deflandre, J., Graepler, F. et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut. 2003; 52: 140–142
CrossRef | PubMed | Scopus (114)

[236]Szumlanski, C.L., Honchel, R., Scott, M.C., and Weinshilboum, R.M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992; 2: 148–159
CrossRef | PubMed

[237]Hindorf, U., Jahed, K., Bergquist, A., Verbaan, H., Prytz, H., Wallerstedt, S. et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol. 2010; 52: 106–111
Abstract | Full Text | Full Text PDF | PubMed | Scopus (18)

[238]Schramm, C., Herkel, J., Beuers, U., Kanzler, S., Galle, P.R., and Lohse, A.W. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol. 2006; 101: 556–560
CrossRef | PubMed | Scopus (79)

[239]Werner, M., Bjornsson, E., Prytz, H., Lindgren, S., Almer, S., Broome, U. et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?. Scand J Gastroenterol. 2007; 42: 986–991
CrossRef | PubMed | Scopus (32)

[240]Francella, A., Dyan, A., Bodian, C., Rubin, P., Chapman, M., and Present, D.H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003; 124: 9–17
Abstract | Full Text | Full Text PDF | PubMed | Scopus (210)

[241]Akbari, M., Shah, S., Velayos, F.S., Mahadevan, U., and Cheifetz, A.S. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19: 15–22
CrossRef | PubMed | Scopus (41)

[242]Adamowicz, R., Trzeciak-Supel, E., Smolarczyk, R., Przybylkowska, M., and Marianowska, S. Subsequent pregnancy (twin) in woman with autoimmunological hepatitis. Ginekol Pol. 2005; 76: 742–746
PubMed

[243]Christopher, V., Al-Chalabi, T., Richardson, P.D., Muiesan, P., Rela, M., Heaton, N.D. et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl. 2006; 12: 1138–1143
CrossRef | PubMed | Scopus (64)

[244]Rosenkrantz, J.G., Githens, J.H., Cox, S.M., and Kellum, D.L. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol. 1967; 97: 387–394
PubMed

[245]Mohamed-Ahmed, O., Nelson-Piercy, C., Bramham, K., Gao, H., Kurinczuk, J.J., Brocklehurst, P. et al. Pregnancy outcomes in liver and cardiothoracic transplant recipients: a UK national cohort study. PLoS One. 2014; 9: e89151
CrossRef | PubMed

[246]Angelberger, S., Reinisch, W., Messerschmidt, A., Miehsler, W., Novacek, G., Vogelsang, H. et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011; 5: 95–100
PubMed | Scopus (0)

[247]Christensen, L.A., Dahlerup, J.F., Nielsen, M.J., Fallingborg, J.F., and Schmiegelow, K. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008; 28: 1209–1213
CrossRef | PubMed | Scopus (59)

[248]Gregorio, G.V., Portmann, B., Reid, F., Donaldson, P.T., Doherty, D.G., McCartney, M. et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997; 25: 541–547
CrossRef | PubMed | Scopus (374)

[249]Czaja, A.J., Carpenter, H.A., Santrach, P.J., and Moore, S.B. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993; 105: 1502–1507
Abstract | Full Text PDF | PubMed

[250]Maggiore, G., Bernard, O., Hadchouel, M., Hadchouel, P., Odievre, M., and Alagille, D. Treatment of autoimmune chronic active hepatitis in childhood. J Pediatr. 1984; 104: 839–844
Abstract | Full Text PDF | PubMed | Scopus (61)

[251]Maggiore, G., Veber, F., Bernard, O., Hadchouel, M., Homberg, J.C., Alvarez, F. et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr. 1993; 17: 376–381
CrossRef | PubMed

[252]Banerjee, S., Rahhal, R., and Bishop, W.P. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2006; 43: 353–356
CrossRef | PubMed | Scopus (18)

[253]Aw, M.M., Dhawan, A., Samyn, M., Bargiota, A., and Mieli-Vergani, G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009; 51: 156–160
Abstract | Full Text | Full Text PDF | PubMed | Scopus (57)

[254]Debray, D., Maggiore, G., Girardet, J.P., Mallet, E., and Bernard, O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr. 1999; 135: 111–114
Abstract | Full Text | Full Text PDF | PubMed

[255]Alvarez, F., Ciocca, M., Canero-Velasco, C., Ramonet, M., de Davila, M.T., Cuarterolo, M. et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999; 30: 222–227
Abstract | Full Text | Full Text PDF | PubMed | Scopus (156)

[256]Malekzadeh, R., Nasseri-Moghaddam, S., Kaviani, M.J., Taheri, H., Kamalian, N., and Sotoudeh, M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001; 46: 1321–1327
CrossRef | PubMed | Scopus (79)

[257]Cuarterolo, M., Ciocca, M., Velasco, C.C., Ramonet, M., Gonzalez, T., Lopez, S. et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr. 2006; 43: 635–639
CrossRef | PubMed

[258]Woynarowski, M., Nemeth, A., Baruch, Y., Koletzko, S., Melter, M., Rodeck, B. et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013; 163: e1
Abstract | Full Text PDF | PubMed

[259]Worns, M.A., Teufel, A., Kanzler, S., Shrestha, A., Victor, A., Otto, G. et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008; 103: 138–146
CrossRef | PubMed | Scopus (24)

[260]Czaja, A.J. and Carpenter, H.A. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006; 43: 532–538
CrossRef | PubMed | Scopus (99)

[261]Miyake, Y., Iwasaki, Y., Takaki, A., Kobashi, H., Sakaguchi, K., and Shiratori, Y. Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern Med. 2007; 46: 1945–1949
CrossRef | PubMed

[262]Granito, A., Muratori, L., Pappas, G., Muratori, P., Ferri, S., Cassani, F. et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther. 2005; 21: 1273–1277
CrossRef | PubMed | Scopus (28)

[263]Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F. et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22: 696–699
Abstract | Full Text PDF | PubMed | Scopus (2781)

[264]Reginster, J.Y. and Burlet, N. Osteoporosis: a still increasing prevalence. Bone. 2006; 38: S4–S9
Abstract | Full Text | Full Text PDF | PubMed | Scopus (255)

[265]De Vries, F., Bracke, M., Leufkens, H.G., Lammers, J.W., Cooper, C., and Van Staa, T.P. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007; 56: 208–214
CrossRef | PubMed | Scopus (100)

[266]Curtis, J.R. and Saag, K.G. Prevention and treatment of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep. 2007; 5: 14–21
CrossRef | PubMed | Scopus (12)

[267]American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology. 2003; 125: 937–940
Abstract | Full Text | Full Text PDF | PubMed | Scopus (30)

[268]Kornbluth, A., Hayes, M., Feldman, S., Hunt, M., Fried-Boxt, E., Lichtiger, S. et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines’ criteria. Am J Gastroenterol. 2006; 101: 1546–1550
CrossRef | PubMed | Scopus (42)

[269]Long, M.D., Thiny, M.T., Sandler, R.S., and Gangarosa, L.M. Bone health in a tertiary-care gastroenterology and hepatology population. Dig Dis Sci. 2010; 55: 2263–2269
CrossRef | PubMed | Scopus (1)

[270]Collier, J. Bone disorders in chronic liver disease. Hepatology. 2007; 46: 1271–1278
CrossRef | PubMed | Scopus (104)

[271]Pares, A. and Guanabens, N. Treatment of bone disorders in liver disease. J Hepatol. 2006; 45: 445–453
Abstract | Full Text | Full Text PDF | PubMed | Scopus (26)

[272]Yeoman, A.D., Westbrook, R.H., Zen, Y., Bernal, W., Al-Chalabi, T., Wendon, J.A. et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome. J Hepatol. 2014; 61: 876–882
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[273]Verma, S., Maheshwari, A., and Thuluvath, P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology. 2009; 49: 1396–1397
CrossRef | PubMed | Scopus (6)

[274]Potts, J.R. and Verma, S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World J Gastroenterol. 2011; 17: 2070–2075
CrossRef | PubMed | Scopus (0)

[275]Weiler-Normann, C. and Lohse, A.W. Acute autoimmune hepatitis: many open questions. J Hepatol. 2014; 61: 727–729
Abstract | Full Text | Full Text PDF | PubMed | Scopus (5)

[276]Rumbo, C., Emerick, K.M., Emre, S., and Shneider, B.L. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr. 2002; 35: 391–398
CrossRef | PubMed | Scopus (34)

[277]Wusk, B., Kullak-Ublick, G.A., Rammert, C., von Eckardstein, A., Fried, M., and Rentsch, K.M. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2004; 16: 1407–1413
CrossRef | PubMed | Scopus (26)

[278]Dhaliwal, H.K., Anderson, R., Thornhill, E.L., Schneider, S., McFarlane, E., Gleeson, D. et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology. 2012; 56: 1401–1408
CrossRef | PubMed | Scopus (10)

[279]Lohse, A.W. and Gil, H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol. 2011; 54: 837–839
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[280]Selvarajah, V., Montano-Loza, A.J., and Czaja, A.J. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012; 36: 691–707
CrossRef | PubMed | Scopus (14)

[281]Yeoman, A.D., Longhi, M.S., and Heneghan, M.A. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther. 2010; 31: 771–787
PubMed

[282]Hlivko, J.T., Shiffman, M.L., Stravitz, R.T., Luketic, V.A., Sanyal, A.J., Fuchs, M. et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008; 6: 1036–1040
Abstract | Full Text | Full Text PDF | PubMed | Scopus (45)

[283]Hennes, E.M., Oo, Y.H., Schramm, C., Denzer, U., Buggisch, P., Wiegard, C. et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol. 2008; 103: 3063–3070
CrossRef | PubMed | Scopus (80)

[284]Sharzehi, K., Huang, M.A., Schreibman, I.R., and Brown, K.A. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010; 24: 588–592
PubMed

[285]Sciveres, M., Caprai, S., Palla, G., Ughi, C., and Maggiore, G. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther. 2004; 19: 209–217
CrossRef | PubMed | Scopus (20)

[286]Sherman, K.E., Narkewicz, M., and Pinto, P.C. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994; 21: 1040–1047
Abstract | Full Text PDF | PubMed | Scopus (70)

[287]Fernandes, N.F., Redeker, A.G., Vierling, J.M., Villamil, F.G., and Fong, T.L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999; 94: 241–248
CrossRef | PubMed | Scopus (102)

[288]Aqel, B.A., Machicao, V., Rosser, B., Satyanarayana, R., Harnois, D.M., and Dickson, R.C. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004; 38: 805–809
CrossRef | PubMed | Scopus (75)

[289]Larsen, F.S., Vainer, B., Eefsen, M., Bjerring, P.N., and Adel Hansen, B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007; 13: 3232–3236
CrossRef | PubMed

[290]Tannous, M.M., Cheng, J., Muniyappa, K., Farooq, I., Bharara, A., Kappus, M. et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011; 34: 405–407
CrossRef | PubMed | Scopus (15)

[291]Kanzler, S., Gerken, G., Dienes, H.P., Meyer zum Buschenfelde, K.H., and Lohse, A.W. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis–report of three cases. Z Gastroenterol. 1997; 35: 571–578
PubMed

[292]Burak, K.W., Urbanski, S.J., and Swain, M.G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol. 1998; 29: 990–993
Abstract | Full Text PDF | PubMed | Scopus (68)

[293]Burak, K.W., Swain, M.G., Santodomingo-Garzon, T., Lee, S.S., Urbanski, S.J., Aspinall, A.I. et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013; 27: 273–280
PubMed

[294]Weiler-Normann, C., Schramm, C., Quaas, A., Wiegard, C., Glaubke, C., Pannicke, N. et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013; 58: 529–534
Abstract | Full Text | Full Text PDF | PubMed | Scopus (25)

[295]Borman, M.A., Urbanski, S., and Swain, M.G. Anti-TNF-induced autoimmune hepatitis. J Hepatol. 2014; 61: 169–170
Abstract | Full Text | Full Text PDF | PubMed

[296]Weiler-Normann, C., Herkel, J., Schramm, C., and Lohse, A.W. Reply to: “anti-TNF-induced autoimmune hepatitis”. J Hepatol. 2014; 61: 170–171
Abstract | Full Text | Full Text PDF | PubMed

[297]Kerkar, N., Dugan, C., Rumbo, C., Morotti, R.A., Gondolesi, G., Shneider, B.L. et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant. 2005; 5: 1085–1089
CrossRef | PubMed | Scopus (70)

[298]Chatrath, H., Allen, L., and Boyer, T.D. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014; 127: 1128–1131
Abstract | Full Text | Full Text PDF | PubMed

[299]Floreani, A., Liberal, R., Vergani, D., and Mieli-Vergani, G. Autoimmune hepatitis: contrasts and comparisons in children and adults – A comprehensive review. J Autoimmun. 2013; 46: 7–16
CrossRef | PubMed | Scopus (12)

[300]Kerkar, N., Annunziato, R.A., Foley, L., Schmeidler, J., Rumbo, C., Emre, S. et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr. 2006; 43: 629–634
CrossRef | PubMed

[301]Soanes, C. and Timmons, S. Improving transition: a qualitative study examining the attitudes of young people with chronic illness transferring to adult care. J Child Health Care. 2004; 8: 102–112
CrossRef | PubMed | Scopus (41)

[302]Kelly, D. Theory to reality: the role of the transition nurse coordinator. Br J Nurs. 2014; 23: 888–894
CrossRef | PubMed

[303]Pratt, D.S., Flavin, D.P., and Kaplan, M.M. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996; 110: 271–274
Abstract | Full Text PDF | PubMed | Scopus (67)

[304]Chazouilleres, O., Wendum, D., Serfaty, L., Rosmorduc, O., and Poupon, R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006; 44: 400–406
Abstract | Full Text | Full Text PDF | PubMed | Scopus (110)

[305]Joshi, S., Cauch-Dudek, K., Wanless, I.R., Lindor, K.D., Jorgensen, R., Batts, K. et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002; 35: 409–413
CrossRef | PubMed | Scopus (113)

[306]Rust, C. and Beuers, U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol. 2008; 14: 3368–3373
CrossRef | PubMed | Scopus (77)

[307]Ozaslan, E., Efe, C., Heurgue-Berlot, A., Kav, T., Masi, C., Purnak, T. et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014; 12: 863–869
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[308]Poupon, R., Chazouilleres, O., Corpechot, C., and Chretien, Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006; 44: 85–90
CrossRef | PubMed | Scopus (84)

[309]Floreani, A., Rizzotto, E.R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L. et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005; 100: 1516–1522
CrossRef | PubMed | Scopus (97)

[310]Al-Chalabi, T., Portmann, B.C., Bernal, W., McFarlane, I.G., and Heneghan, M.A. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008; 28: 209–220
CrossRef | PubMed | Scopus (53)

[311]Gautam, M., Cheruvattath, R., and Balan, V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006; 12: 1813–1824
CrossRef | PubMed | Scopus (130)

[312]Carbone, M. and Neuberger, J.M. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014; 60: 210–223
Abstract | Full Text | Full Text PDF | PubMed | Scopus (6)

[313]Gonzalez-Koch, A., Czaja, A.J., Carpenter, H.A., Roberts, S.K., Charlton, M.R., Porayko, M.K. et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001; 7: 302–310
CrossRef | PubMed | Scopus (113)

[314]Salcedo, M., Vaquero, J., Banares, R., Rodriguez-Mahou, M., Alvarez, E., Vicario, J.L. et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002; 35: 349–356
CrossRef | PubMed | Scopus (118)

[315]Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D., and Berenguer, J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002; 97: 2408–2414
CrossRef | PubMed

[316]Liu, B., Balkwill, A., Reeves, G., and Beral, V. Million Women Study C. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010; 340: c912
CrossRef | PubMed | Scopus (35)

[317]European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167–185
Abstract | Full Text | Full Text PDF | PubMed | Scopus (955)

[318]O’Leary, J.G., Zachary, K., Misdraji, J., and Chung, R.T. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis. 2008; 46: e12–e14
CrossRef | PubMed | Scopus (18)

[319]Puius, Y.A., Dove, L.M., Brust, D.G., Shah, D.P., and Lefkowitch, J.H. Three cases of autoimmune hepatitis in HIV-infected patients. J Clin Gastroenterol. 2008; 42: 425–429
CrossRef | PubMed | Scopus (14)

[320]Wan, D.W., Marks, K., Yantiss, R.K., and Talal, A.H. Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDS. 2009; 23: 407–413
CrossRef | PubMed | Scopus (5)

[321]Dyson, J.K., Webb, G., Hirschfield, G.M., Lohse, A., Beuers, U., Lindor, K. et al. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015; 62: 208–218
Abstract | Full Text | Full Text PDF | PubMed | Scopus (2)

[322]Héon-Klin, V., Halbach, A., Schlangen, M., and Schnieders, B. Developing a national plan for rare diseases in Germany through concerted action: the national action league for people with rare diseases. Orphanet J Rare Dis. 2012; 7 (A9–A9)
CrossRef

[323]Olauson, A. The Agrenska centre: a socioeconomic case study of rare diseases. Pharmacoeconomics. 2002; 20: 73–75
CrossRef | PubMed

[324]Fogarty, L.A., Curbow, B.A., Wingard, J.R., McDonnell, K., and Somerfield, M.R. Can 40 seconds of compassion reduce patient anxiety?. J Clin Oncol. 1999; 17: 371–379
PubMed

[325]Talwalkar, J.A. and Kim, W.R. Medical and economic impact of autoimmune hepatitis. Clin Liver Dis. 2002; 6: 649–667
Abstract | Full Text | Full Text PDF | PubMed

[326]van der Plas, S.M., Hansen, B.E., de Boer, J.B., Stijnen, T., Passchier, J., de Man, R.A. et al. Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. Qual Life Res. 2007; 16: 375–388
CrossRef | PubMed | Scopus (6)

[327]Gulati, R., Radhakrishnan, K.R., Hupertz, V., Wyllie, R., Alkhouri, N., Worley, S. et al. Health-related quality of life in children with autoimmune liver disease. J Pediatr Gastroenterol Nutr. 2013; 57: 444–450
CrossRef | PubMed | Scopus (1)